Global Open-Angle Glaucoma Therapeutics Market 2019–2023
A
key factor driving the growth of the global open-angle glaucoma
therapeutics market size is the increasing demand for combination drugs.
Monotherapy has been the most preferred choice for the treatment of
open-angle glaucoma. However, in some cases, monotherapy fails to
control IOP effectively, and it can lose its effectiveness over time.
This situation can be resolved by using combination therapy that aims at
different targets and pathways to combat the disease with minimal
adverse effects. Thus, the advantages of combination therapy over
monotherapy is expected to increase their use, thereby driving the
open-angle glaucoma therapy market growth during the forecast period.
Global open-angle glaucoma therapeutics market: Strategic alliances
Pharmaceutical
companies are increasingly focusing on the development of new drugs to
meet the requirement of novel medication for the treatment of open-angle
glaucoma. This has resulted in the formation of collaborations between
numerous companies, which is likely to speed up the development process
and also increase the investments in research. Thus, the strategic
alliances between vendors are expected to be one of the key open-angle glaucoma therapeutics market trends during the forecast period.
Global open-angle glaucoma therapeutics market: Segmentation analysis
This
market research report segments the global open-angle glaucoma
therapeutics market by product (PGAs, and Non-PGAs), and geographic
regions (North America, Europe, Asia, and ROW).
The
North American region led the open-angle glaucoma therapeutics market
in 2018, followed by Europe, Asia, and ROW respectively. The growth of
the open-angle glaucoma therapeutics market in North America can be
attributed to the increasing prevalence of open-angle glaucoma due to
the presence of population and high-risk factors in the region.
Comments
Post a Comment